Ambrisentan and its role in the management of pulmonary arterial hypertension

Drugs of Today

Volumn 44, Issue 12, 2008, Pages 875-885

  MacIntyre, Ian M ^a   Dhaun, Neeraj ^a   Goddard, Jane ^a   Webb, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; SILDENAFIL; SITAXSENTAN; SULFONAMIDE; THROMBOXANE A2; WARFARIN;

ABDOMINAL PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; LIVER DISEASE; LIVER TOXICITY; LONG TERM CARE; NONHUMAN; NOSE CONGESTION; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; RECEPTOR, ENDOTHELIN A;

EID: 61949463985     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2008.44.12.1310761     Document Type: Review

References (65)

1. Galiè N, Torbicki, A., Barst, R. et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004, 25(24): 2243-78.
2. Chin, K.M., Rubin, L.J. Pulmonary arterial hypertension. J Am Coll Cardiol 2008, 51(16): 1527-38.
3. D'Alonzo G.E., Barst, R.J., Ayres, S.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991, 115(5): 343-9.
4. Simonneau G., Galiè, N., Rubin, L.J. et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(12 Suppl. S): 5S-12S.
5. Barst, RJ, McGoon, M., Torbicki, A. et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(12 Suppl. S): 40S-47S.
6. Budhiraja R, Tuder, R.M., Hassoun, P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109(2): 159-65.
7. Giaid A, Yanagisawa, M., Langleben, D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328(24): 1732-9.
8. Christman, B.W., McPherson, C.D., Newman, J.H. et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992, 327(2): 70-5.
9. Barst, R.J., Rubin, L.J., Long, W.A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996, 334(5): 296-302.
10. McLaughlin, V.V., Shillington, A., Rich, S. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002, 106(12): 1477-82.
11. Dhaun, N., Pollock, D.M., Goddard, J., Webb, D.J. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007, 28(11): 573-9.
12. Yanagisawa, M., Kurihara, H., Kimura, S. et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332(6163): 411-5.
13. Kedzierski, R.M., Yanagisawa, M. Endothelin system: The double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001, 41: 851-76.
14. Battistini, B., Criailler, P., D'Orléans-Juste, P., Brière, N., Sirois, P.. Growth regulatory properties of endothelins. Peptides 1993, 14(2): 385-99.
15. Shi-Wen, X, Denton, C.P., Dashwood, M.R. et al. Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. J Invest Dermatol 2001, 116(3): 417-25.
16. Liu, S., Premont, R.T., Kontos, C.D., Huang, J., Rockey, D.C. Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein beta gamma subunit signaling to protein kinase B/Akt. J Biol Chem 2003, 278(50): 49929-35.
17. McCulloch, K.M., Docherty, C.C., Morecroft, I., MacLean, M.R. Endothelin B receptor-mediated contraction in human pulmonary resistance arteries. Br J Pharmacol 1996, 119(6): 1125-30.
18. Dupuis, J., Stewart, D.J., Cernacek, P., Gosselin, G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996, 94(7): 157-84.
19. Stewart, D.J., Levy, R.D., Cernacek, P., Langleben, D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Int Med 1991, 114(6): 464-9.
20. Rubens, C., Ewert, R., Halank, M. et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001, 120(5): 1562-9.
21. Cacoub, P., Dorent, R., Nataf, P. et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc Res 1997, 33(1): 196-200.
22. Bressollette, E., Dupuis, J., Bonan, R., Doucet, S., Cernacek, P., Tardif, J.C. Intravascular ultrasound assessment of pulmonary vascular disease in patients with pulmonary hypertension. Chest 2001, 120(3): 809-15.
23. Galie, N., Grigioni, F., Bacchi-Reggiani, L. et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest 1996, 26: A48.
24. Langleben, D., Dupuis, J., Langleben, I. et al. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest 2006, 129(3): 689-95.
25. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002, 165(3): 398-405.
26. Soma, S., Takahashi, H., Muramatsu, M., Oka, M., Fukuchi, Y. Localization and distribution of endothelin receptor subtypes in pulmonary vasculature of normal and hypoxia-exposed rats. Am J Respir Cell Mol Biol 1999, 20(4): 620-30.
27. Ivy, D., McMurtry, I.F., Yanagisawa, M. et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001, 280(5): L1040-8.
28. Ivy, D.D., McMurtry, I.F., Colvin, K. et al. Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: A new model of severe pulmonary arterial hypertension. Circulation 2005, 111(22): 2988-96.
29. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., Kohan, D.E. Profile of past and current clinical trials involving endothelin receptor antagonists: The novel "-sentan" class of drug. Exp Biol Med (Maywood) 2006, 231(6): 653-95.
30. Wu, C., Chan, M.F., Stavros, F. et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997, 40(11): 1690-7.
31. A-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995, 269(5, Pt. 1): L690-7.
32. Chen, S.J., Chen, Y.F., Opgenorth, T.J. et al. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. J Cardiovasc Pharmacol 1997, 29(6): 713-25.
33. Chen, S.J., Chen, Y.F., Meng, Q.C., Durand, J., Dicarlo, V.S., Oparil, S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995, 79(6): 2122-31.
34. Davenport, A.P., Maguire, J.J. Endothelin. Handb Exp Pharmacol 2006, (176, Pt. 1): 295-329.
35. Channick, R.N., Simonneau, G., Sitbon, O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001, 358(9288): 1119-23.
36. Rubin, L.J., Badesch, D.B., Barst, R.J. et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346(12): 896-903.
37. McLaughlin, V.V., Sitbon, O., Badesch, D.B. et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005, 25(2): 244-9.
38. Barst, R.J., Langleben, D., Frost, A. et al.; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004, 169(4): 441-7.
39. Barst, R.J., Langleben, D., Badesch, D. et al.; STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006, 47(10): 2049-56.
40. Bolli, M.H., Marfurt, J., Grisostomi, C. et al. Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists. J Med Chem 2004, 47(11): 2776-95.
41. B receptor selectivity of endothelin-1 receptor antagonists. J Am Coll Cardiol 2006, 47: 307A.
42. Food and Drug Administration / CDER LETAIRIS® (ambrisentan tablets). Clinical Pharmacology. 2007, 3: 98-99. Available at:http://www.fda.gov/cder/foi/ nda/2007/022081s000_ClinPharmR_P3.pdf. Accessed on August 19, 2008.
43. Goddard, J, Johnston, N.R., Hand, M.F. et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: A comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109(9): 1186-93.
44. Givertz, M.M., Colucci, W.S., LeJemtel, T.H. et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 2000, 101(25): 2922-7.
45. European Medicines Agency. Summary of Product Characteristics (ambrisentan). 10-11. Available at: http://www.emea.europa.eu/humandocs/PDFs/ EPAR/volibris/H-839-PI-en.pdf. Accessed on August 19, 2008.
46. Food and Drug Administration. Center for Drug Evaluation and Research. Application Number: 22-081. Pharmacology Review (ambrisentan). 29-60. Available at: http://www.fda.gov/cder/foi/nda/2007/022081s000_PharmR_P1.pdf. Accessed on August 19, 2008.
47. Kenyon, K.W., Nappi, J.M. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003, 37(7-8): 1055-62.
48. Gabbay, E., Fraser, J., McNeil, K. Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2007, 3(6): 887-900.
49. European Medicines Agency. Thelin - Scientific Discussion. 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/thelin/H-679-en6. pdf. Accessed on September 17, 2008.
50. Gerber, M.J., Dufton, C., Pentikis, H., Zhu, L., Hossein, A. Ghofrani, M.D.. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin. Chest 2006, 130: Abst 256S.
51. Galiè, N., Badesch, D., Oudiz, R. et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46(3): 529-35.
52. Oudiz, R.J., Torres, F., Frost, A.E., Badesch, D.B. ARIES-1: A placebo-controlled efficacy and safety study of Ambrisentan in patients with pulmonary arterial hypertension. Chest 2006, 130: Abst 121S.
53. Oudiz, R.J. et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: Results of the ARIES-2 study. International Conference of the American Thoracic Society, May 19-24 2006: 3: Abst A728.
54. Dufton, C. et al. No clinically relevant pharmacokinetic interaction between ambrisentan and sildenafil. Chest 2006, 130: Abst 254S.
55. Galiè, N., Olschewski, H., Oudiz, R.J. et al.; ARIES Group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117(23): 3010-9.
56. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002, 166(1): 111-7.
57. Leuchte, H.H., Holzapfel, M., Baumgartner, R.A. et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004, 43(5): 764-70.
58. Fijalkowska, A., Kurzyna, M., Torbicki, A. et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129(5): 1313-21.
59. Cheng, J. W. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008, 30(5): 825-33.
60. Sandoval, J., Bauerle, O., Palomar, A. et al. Survival in primary pulmonary hypertension. Validation of a prognostic equation. Circulation 1994, 89(4): 1733-44.
61. McGoon MD, et al. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities. Chest 2006, 130: Abst 254S.
62. Korn, J.H., Mayes, M., Matucci Cerinic, M. et al. Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50(12): 3985-93.
63. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M., Charlon, V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. New Engl J Med 1998, 338(12): 784-90.
64. Dhaun, N., Goddard, J., Webb, D.J. The endothelin system and its antagonism in chronic kidney disease. J Am Soc Nephrol 2006, 17(4): 943-55.
65. Nelson, J.B., Nabulsi, A.A., Vogelzang, N.J. et al. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 2003, 169(3): 1143-9.